...
首页> 外文期刊>Molecular diagnosis & therapy >Identification of Candidate Biomarkers for Transplant Rejection from Transcriptome Data: A Systematic Review
【24h】

Identification of Candidate Biomarkers for Transplant Rejection from Transcriptome Data: A Systematic Review

机译:从转录组数据移植抑制的候选生物标志物的鉴定:系统审查

获取原文
获取原文并翻译 | 示例
           

摘要

BackgroundTraditional methods for rejection control in transplanted patients are considered invasive, risky, and prone to sampling errors. Using molecular biomarkers as an alternative protocol tobiopsies, for monitoring rejection may help to mitigate some of these problems, increasing the survival rates and well-being of patients. Recent advances in omics technologies provide an opportunity for screening new molecular biomarkers to identify thosewith clinical utility.ObjectiveThis systematic literature review (SLR) aimed to summarize existing evidence derived from large-scale expression profiling regarding differentially expressed mRNA and miRNA in graft rejection, highlighting potential molecular biomarkers in transplantation.MethodsThe study was conducted following PRISMA methodology and the BiSLR guide for performing SLR in bioinformatics. PubMed, ScienceDirect, and EMBASE were searched for publications from January 2001 to January 2018, and studies (i) aiming at the identification of transplant rejection biomarkers, (ii) including human subjects, and (iii) applying methodologies for differential expression analysis from large-scale expression profiling were considered eligible. Differential expression patterns reported for genes and miRNAs in rejection were summarized from both cross-organ and organ-specific perspectives, and pathways enrichment analysis was performed for candidate biomarkers to interrogate their functional role in transplant rejection.ResultsA total of 821 references were collected, resulting in 604 studies after removal of duplicates. After application of inclusion and exclusion criteria, 33 studies were included in our analysis. Among the 1517 genes and 174 miRNAs identifed, CXCL9, CXCL10, STAT1, hsa-miR-142-3p, and hsa-miR-155 appeared to be particularly promising as biomarkers in transplantation, with an increased expression associated with transplant rejection in multiple organs. In addition, hsa-miR-28-5p was consistently decreased in samplestaken from rejected organs.ConclusionDespite the need for further research to fill existing knowledge gaps, transcriptomic technologies have a relevant role in the discovery of accurate biomarkers for transplant rejection diagnostics. Studies have reported consistent evidence of differential expression associated with transplant rejection, although issues such as experimental heterogeneity hinder a more systematic characterization of observed molecular changes. Special attention has been giving to large-scale mRNA expression profiling in rejection, whereas there is still room for improvements in thecharacterization of miRnome in this condition.PROSPERO Registration NumberCRD42018083321.
机译:移植患者中排斥对照的背景分隔方法被认为是侵入性的,危险性和容易取样误差。使用分子生物标志物作为替代方案TobioSIES,对于监测拒绝可能有助于减轻一些问题,增加患者的存活率和福祉。 OMICS技术的最新进展为筛选新的分子生物标志物提供了识别临床实用程序的机会,以识别临床实用程序.Bobjectivethis系统文献综述(SLR)旨在总结从差异表达差异表达的差异表达的mRNA和miRNA中源自大规模表达分析的现有证据,突出潜力移植中的分子生物标志物。普遍方法和用于在生物信息学中进行SLR的BISLR指南进行研究。从2001年1月到2018年1月的出版物搜索了PubMed,ScieCentirect和Embase,以及旨在鉴定移植排斥生物标志物(II)的研究(i),包括人类受试者,(iii)应用差异表达分析的方法被视为符合条件的绩效表达分析。从交叉器官和器官特异性观察结果总结了对基因和miRNA报告的差异表达模式,并且对候选生物标志物进行途径浓缩分析,以询问其在移植抑制中的功能作用。收集了821次参考的总共821参考文献,产生了在去除重复后的604项研究中。在申请包含和排除标准之后,我们的分析中包含33项研究。在鉴定的1517个基因和174个miRNA中,CXCL9,CXCL10,STAT1,HSA-MIR-142-3P和HSA-MIR-155似乎特别有前途作为移植中的生物标志物,其表达增加与多个器官中的移植排斥相关。此外,HSA-MIR-28-5P从被拒绝的机构持续下降.CONCLUSIONDEMICESTEMITHICATE进一步研究以填补现有的知识差距,转录组技术在发现准确的移植抑制诊断中具有相关的作用。研究报告了与移植抑制相关的差异表达的一致证据,尽管诸如实验性异质性的问题妨碍观察到的分子变化的更系统的表征。特别注意在抑制中赋予大规模的mRNA表达分析,而在此条件下,米罗族的术仍有改进的空间.ProSpero注册NumberCRD42018083321。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号